Bristol Myers Squibb Company reported financial results for the third quarter of 2026 and updated its full-year outlook. The company announced that total revenues for the third quarter increased 7% year-over-year to $13.1 billion. Within this total, the Growth Portfolio generated $7.7 billion in revenues, representing a 12% increase. Legacy Portfolio revenues were $5.4 billion, up 1%.
On a per-share basis, GAAP earnings were $1.05, while non-GAAP earnings were $1.35. Both figures include a net impact of $(0.58) per share related to Acquired IPRD charges and licensing income.
Guidance for the full year 2026 has been raised to a range of $49.75 billion to $50.25 billion. The company also updated its non-GAAP EPS range to $6.35 to $6.55, which includes a net impact of $(0.60) per share from Acquired IPRD charges and licensing income.
Key product performance highlights for the quarter included Opdivo Qvantig, which saw revenue increase by more than 200%, and Breyanzi, which increased 43%. Eliquis drove growth in the Legacy Portfolio, increasing 39%.
During the quarter, the company announced several pipeline milestones. The U.S. Food and Drug Administration approved Zenbexus, a first-in-class CELMoD, for the treatment of multiple myeloma. Additionally, the company reported positive topline results from Phase 3 trials evaluating RYZ101 for gastroenteropancreatic neuroendocrine tumors and admilparant for idiopathic pulmonary fibrosis.
